Celldex Therapeutics, Inc. CLDX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Revenue compounded at −26.9% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 41 cents this year.
The 17-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.3 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.3 | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | ◌ | −0.0 | −0.0 | ◌ | −0.0 | −0.0 | ◌ | ◌ | ◌ | 0.0 | 0.0 | ◌ | ◌ | −0.0 |
| Net income $B | −0.3 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.2 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.2 | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −3.90 | −2.45 | −2.92 | −2.40 | −1.64 | −2.02 | −3.51 | −14.48 | −10.86 | −18.99 | −1.31 | −1.32 | −1.02 | −1.02 | −1.13 | −0.08 | −1.84 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | −40.6 | −26.8 | −37.4 | −30.1 | −22.4 | −39.4 | −46.7 | −83.9 | −37.1 | −46.3 | −50.7 | −44.4 | −39.2 | −71.9 | −62.2 | −3.4 | −49.5 |
| Shares out B | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 | 0.04 | 0.02 | 0.01 | 0.14 | 0.12 | 0.10 | 0.09 | 0.09 | 0.06 | 0.04 | 0.03 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
This company against its peers
Company facts, as filed
Reconciled in 17 of the 17 fiscal years we could check. Nine checks were skipped: cost of revenue is not tagged before 2016. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.